p.112 抽出テキスト

integration into clinical practice. JACC Cardiovasc Imaging 2008;1:536–55. https://doi. org/10.1016/j.jcmg.2008.05.009 743. Kunadian V, Zaman A, Qiu W. Revascularization among patients with severe left ventricular dysfunction: a meta-analysis of observational studies. Eur J Heart Fail 2011;13: 773–84. https://doi.org/10.1093/eurjhf/hfr037 744. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002;39:1151–8. https://doi. org/10.1016/s0735-1097(02)01726-6 745. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007;50:2002–12. https://doi.org/10.1016/j.jacc.2007.09.006 746. Mc Ardle B, Shukla T, Nichol G, deKemp RA, Bernick J, Guo A, et al. Long-term followup of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. Circ Cardiovasc Imaging 2016;9:e004331. https://doi.org/ 10.1161/circimaging.115.004331 747. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009;2:1060–8. https://doi.org/10.1016/j.jcmg.2009.02.017 748. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging 2013;6:363–72. https://doi.org/10.1161/circimaging.112.000138 749. Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, et al. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). Circulation 2016;134:1314–24. https://doi.org/10.1161/CIRCULATIONAHA.116.024800 750. Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med 2019;381: 739–48. https://doi.org/10.1056/NEJMoa1807365 751. Wolff G, Dimitroulis D, Andreotti F, Kołodziejczak M, Jung C, Scicchitano P, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail 2017;10:e003255. https://doi.org/10.1161/circheartfailure.116.003255 752. Sun LY, Gaudino M, Chen RJ, Bader Eddeen A, Ruel M. Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting. JAMA Cardiol 2020;5:631–41. https://doi.org/10.1001/jamacardio.2020.0239 753. Völz S, Redfors B, Angerås O, Ioanes D, Odenstedt J, Koul S, et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2021;42: 2657–64. https://doi.org/10.1093/eurheartj/ehab273 754. Ono M, Garg S, Onuma Y, Serruys PW. Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data? Eur Heart J 2021;42: 2665–9. https://doi.org/10.1093/eurheartj/ehab349 755. Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, et al. Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 trial. JAMA Cardiol 2023;8:1154–61. https://doi.org/10.1001/jamacardio.2023.3803 756. Ryan M, Morgan H, Chiribiri A, Nagel E, Cleland J, Perera D. Myocardial viability testing: all STICHed up, or about to be REVIVED? Eur Heart J 2022;43:118–26. https://doi.org/ 10.1093/eurheartj/ehab729 757. Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, et al. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117:1283–91. https://doi.org/10.1161/circulationaha.107.743963 758. Gaudino M, Andreotti F, Kimura T. Current concepts in coronary artery revascularisation. Lancet 2023;401:1611–28. https://doi.org/10.1016/S0140-6736(23)00459-2 759. Kim T, Kang DY, Kim S, Lee JH, Kim AR, Lee YJ, et al. Impact of complete or incomplete revascularization for left main coronary disease: the extended PRECOMBAT study. JACC Asia 2023;3:65–74. https://doi.org/10.1016/j.jacasi.2022.10.007 760. Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation 2013;128:141–51. https://doi.org/10.1161/CIRCULATIONAHA.113.001803 761. Gallinoro E, Paolisso P, Di Gioia G, Bermpeis K, Fernandez-Peregrina E, Candreva A, et al. Deferral of coronary revascularization in patients with reduced ejection fraction based on physiological assessment: impact on long-term survival. J Am Heart Assoc 2022;11:e026656. https://doi.org/10.1161/JAHA.122.026656 762. Ahn JM, Park DW, Lee CW, Chang M, Cavalcante R, Sotomi Y, et al. Comparison of stenting versus bypass surgery according to the completeness of revascularization in severe coronary artery disease: patient-level pooled analysis of the SYNTAX, PRECOMBAT, and BEST trials. JACC Cardiovasc Interv 2017;10:1415–24. https://doi. org/10.1016/j.jcin.2017.04.037 763. Girerd N, Magne J, Rabilloud M, Charbonneau E, Mohamadi S, Pibarot P, et al. The impact of complete revascularization on long-term survival is strongly dependent on age. Ann Thorac Surg 2012;94:1166–72. https://doi.org/10.1016/j.athoracsur.2012.05.023 764. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, et al. A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. Eur Heart J 2018;39: 2484–93. https://doi.org/10.1093/eurheartj/ehy220 765. Lee SW, Lee PH, Ahn JM, Park DW, Yun SC, Han S, et al. Randomized trial evaluating percutaneous coronary intervention for the treatment of chronic total occlusion. Circulation 2019;139:1674–83. https://doi.org/10.1161/CIRCULATIONAHA.118. 031313 766. Simsek B, Kostantinis S, Karacsonyi J, Alaswad K, Megaly M, Karmpaliotis D, et al. A systematic review and meta-analysis of clinical outcomes of patients undergoing chronic total occlusion percutaneous coronary intervention. J Invasive Cardiol 2022; 34:E763–75. 767. Werner GS, Hildick-Smith D, Martin Yuste V, Boudou N, Sianos G, Gelev V, et al. Three-year outcomes of a randomized multicentre trial comparing revascularization and optimal medical therapy for chronic total coronary occlusions (EuroCTO). EuroIntervention 2023;19:571–9. https://doi.org/10.4244/eij-d-23-00312 768. Takahashi K, Serruys PW, Gao C, Ono M, Wang R, Thuijs DJFM, et al. Ten-year allcause death according to completeness of revascularization in patients with threevessel disease or left main coronary artery disease: insights from the SYNTAX Extended survival study. Circulation 2021;144:96–109. https://doi.org/10.1161/ CIRCULATIONAHA.120.046289 769. Leviner DB, Torregrossa G, Puskas JD. Incomplete revascularization: what the surgeon needs to know. Ann Cardiothorac Surg 2018;7:463–9. https://doi.org/10.21037/acs. 2018.06.07 770. Gaba P, Gersh BJ, Ali ZA, Moses JW, Stone GW. Complete versus incomplete coronary revascularization: definitions, assessment and outcomes. Nat Rev Cardiol 2021;18: 155–68. https://doi.org/10.1038/s41569-020-00457-5 771. Lamy A, Eikelboom J, Sheth T, Connolly S, Bosch J, Fox KAA, et al. Rivaroxaban, aspirin, or both to prevent early coronary bypass graft occlusion: the COMPASS-CABG study. J Am Coll Cardiol 2019;73:121–30. https://doi.org/10.1016/j.jacc.2018.10.048 772. Xenogiannis I, Zenati M, Bhatt DL, Rao SV, Rodés-Cabau J, Goldman S, et al. Saphenous vein graft failure: from pathophysiology to prevention and treatment strategies. Circulation 2021;144:728–45. https://doi.org/10.1161/CIRCULATIONAHA.120. 052163 773. Han Z, Zhang G, Chen Y. Early asymptomatic graft failure in coronary artery bypass grafting: a study based on computed tomography angiography analysis. J Cardiothorac Surg 2023;18:98. https://doi.org/10.1186/s13019-023-02199-0 774. Head SJ, Borgermann J, Osnabrugge RL, Kieser TM, Falk V, Taggart DP, et al. Coronary artery bypass grafting: Part 2—optimizing outcomes and future prospects. Eur Heart J 2013;34:2873–86. https://doi.org/10.1093/eurheartj/eht284 775. Stone GW. Multivessel PCI on its 40th anniversary: finally a match for CABG? Eur Heart J 2017;38:3135–8. https://doi.org/10.1093/eurheartj/ehx528 776. Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, et al. Performance of EuroSCORE II in a large US database: implications for transcatheter aortic valve implantation. Eur J Cardiothorac Surg 2014;46:400–8; discussion 408. https://doi.org/10.1093/ejcts/ezu033 777. Thuijs D, Habib RH, Head SJ, Puskas JD, Taggart DP, Stone GW, et al. Prognostic performance of the Society of Thoracic Surgeons risk score in patients with left main coronary artery disease undergoing revascularisation: a post hoc analysis of the EXCEL trial. EuroIntervention 2020;16:36–43. https://doi.org/10.4244/EIJ-D-19-00417 778. Reichart D, Rosato S, Nammas W, Onorati F, Dalén M, Castro L, et al. Clinical frailty scale and outcome after coronary artery bypass grafting. Eur J Cardiothorac Surg 2018; 54:1102–9. https://doi.org/10.1093/ejcts/ezy222 779. Zhang YJ, Iqbal J, Campos CM, Klaveren DV, Bourantas CV, Dawkins KD, et al. Prognostic value of site SYNTAX score and rationale for combining anatomic and clinical factors in decision making: insights from the SYNTAX trial. J Am Coll Cardiol 2014; 64:423–32. https://doi.org/10.1016/j.jacc.2014.05.022 780. Bonaros N, Van Craenenbroeck E. A good operation is not enough, when it comes to frail patients. Eur J Cardiothorac Surg 2023;64:ezad205. https://doi.org/10.1093/ejcts/ ezad205 781. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005;1:219–27. 782. Byrne RA, Fremes S, Capodanno D, Czerny M, Doenst T, Emberson JR, et al. 2022 Joint ESC/EACTS review of the 2018 guideline recommendations on the revascularization of left main coronary artery disease in patients at low surgical risk and anatomy Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026